Publications

Frank SJ, Busse PM, Lee JJ, Rosenthal DI, Hernandez M, Swanson DM, Garden AS, Gunn GB, Patel SH, Snider JW, Ma DJ, Molitoris JK, Lee NY, Parvathaneni U, McDonald MW, Kalman NS, Lin A, Mohammed N, Henson C, Hyde C, Bajaj GK, Katz SR, Dagan R, Morrison WH, Reddy JP, Fuller CD, Shah SJ, Phan J, Chronowski GM, Mayo L, Sturgis EM, Ferrarotto R, Zhu XR, Zhang X, Wang L, Hutcheson KA, El-Naggar AK, Moreno AC, Lee A, Spiotto MT, Gross ND, Lai SY, Liao JJ, Paly J, Liao Z, Foote RL; University of Texas MD Anderson Cancer Center Clinical Trial Consortium. Proton versus photon radiotherapy for patients with oropharyngeal cancer in the USA: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet. 2026 Jan 10;407(10524):174-184. doi: 10.1016/S0140-6736(25)01962-2. Epub 2025 Dec 11. PMID: 41391462; PMCID: PMC12812248.

Tan NQP, Nargund RS, Douglas EE, Lopez-Olivo MA, Resong PJ, Ishizawa S, Nofal S, Krause K, Volk RJ, Toumazis I. Acceptability and perceptions of personalised risk-based cancer screening among health-care professionals and the general public: a systematic review and meta-analysis. Lancet Public Health. 2025 Feb;10(2):e85-e96. doi: 10.1016/S2468-2667(24)00278-0. PMID: 39909697; PMCID: PMC11817692.

Gendarme S, Irajizad E, Long JP, Fahrmann JF, Dennison JB, Ghasemi SM, Dou R, Volk RJ, Meza R, Toumazis I, Canoui-Poitrine F, Hanash SM, Ostrin EJ. Impact of Comorbidities on the Mortality Benefits of Lung Cancer Screening: A Post-Hoc Analysis of the PLCO and NLST Trials. J Thorac Oncol. 2025 May;20(5):565-576. doi: 10.1016/j.jtho.2025.01.003. Epub 2025 Jan 9. PMID: 39798695; PMCID: PMC12066220.

Ishizawa S, Eghbalizarch M, Nargund RS, Mousavi Janbeh Sarayi SM, Niu J, Hemmati M, Tumbarello M, Schaefer AJ, Lu K, Giordano SH, Meyer LA, Toumazis I. Development and validation of a histology-specific natural history model of ovarian cancer. Am J Obstet Gynecol. 2025 Dec;233(6):615.e1-615.e24. doi: 10.1016/j.ajog.2025.06.063. Epub 2025 Jul 5. PMID: 40618976.

Adjei NN, Haas AM, Sun CC, Zhao H, Yeh PG, Giordano SH, Toumazis I, Meyer LA. Cost of ovarian cancer by the phase of care in the United States. Am J Obstet Gynecol. 2025 Feb;232(2):204.e1-204.e13. doi: 10.1016/j.ajog.2024.08.023. Epub 2024 Aug 17. PMID: 39159781; PMCID: PMC12014244.

Maki KG, Tan NQP, Volk RJ, Toumazis I. Examining Lung Cancer Screening Uptake in the United States: Recent Research and Limitations of Public-Use Data. Cancer Epidemiol Biomarkers Prev. 2025 Jan 9;34(1):9-11. doi: 10.1158/1055-9965.EPI-24-1436. PMID: 39780617.

Hernandez M, Maki KG, Zhao H, Toumazis I, Volk RJ. Lung Cancer Screening among Adults Older than Medicare's Upper Age Eligibility Criteria. Cancer Prev Res (Phila). 2025 Nov 3;18(11):693-702. doi: 10.1158/1940-6207.CAPR-24-0544. PMID: 40625204; PMCID: PMC12478563.

Myers AA, Talwar R, Duan Z, Hensley P, Lotan Y, Williams SB, Luckenbaugh AN, Li R, Kassouf W, Necchi A, Packiam VT, Shore N, Steinberg GD, Witjes JA, Schmidt B, Porten S, Hahn NM, Bree KK, Toumazis I, Zhao H, Kamat AM. Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder. Eur Urol. 2026 Feb;89(2):151-162. doi: 10.1016/j.eururo.2025.09.4137. Epub 2025 Oct 4. PMID: 41046180.

Nofal S, J Ostrin E, Zhang J, Wu J, Scheet P, Antonoff MB, V Heymach J, Toumazis I. Risk of second primary lung cancer among cancer survivors stratified by the site of first primary cancer and the lung cancer screening eligibility status. Int J Cancer. 2025 Sep 1;157(5):941-953. doi: 10.1002/ijc.35452. Epub 2025 Apr 18. PMID: 40249102; PMCID: PMC12232526.

Nargund RS, Ishizawa S, Eghbalizarch M, Yeh P, Mousavi Janbeh Saray SM, Nofal S, Geng Y, Cao P, Ostrin EJ, Meza R, Tammemägi MC, Volk RJ, Lopez-Olivo MA, Toumazis I. Natural history models for lung Cancer: A scoping review. Lung Cancer. 2025 May;203:108495. doi: 10.1016/j.lungcan.2025.108495. Epub 2025 Mar 26. PMID: 40174386; PMCID: PMC12077999.

Adjei NN, Haas A, Sun CC, Zhao H, Yeh PG, Giordano SH, Toumazis I, Meyer LA. Healthcare Costs in the United States by Demographic Characteristics and Comorbidity Status. Value Health. 2025 Feb;28(2):206-214. doi: 10.1016/j.jval.2024.10.3847. Epub 2024 Nov 10. PMID: 39532216.

Neumann AS, Toumazis I, O'Brien JA, Beneventi D, Annam SK, Joy-Thomas A, Volk RJ. Tobacco use and eligibility for lung cancer screening among dental patients at an academic institution in Houston, Texas. Prev Med. 2026 Jan;202:108438. doi: 10.1016/j.ypmed.2025.108438. Epub 2025 Nov 8. PMID: 41213458.

Sarayi SMMJ, Tammemägi M, Meyer LA, Toumazis I. Improving ovarian cancer risk assessment using a machine learning model developed on data from the Prostate Lung Colorectal Ovarian Cancer Screening Trial. Int J Gynecol Cancer. 2025 Oct 31:102771. doi: 10.1016/j.ijgc.2025.102771. Epub ahead of print. PMID: 41339202.

Salehjahromi M, Li H, Showkatian E, Saad MB, Qayati M, Ismail SM, Sujit SJ, Muneer A, Aminu M, Hong L, Han X, Heeke S, Cascone T, Le X, Vokes N, Gibbons DL, Toumazis I, Ostrin EJ, Antonoff MB, Vaporciyan AA, Jaffray D, Kay FU, Carter BW, Wu CC, Godoy MCB, Lee JJ, Gerber DE, Heymach JV, Zhang J, Wu J. Radiomics for Dynamic Lung Cancer Risk Prediction in USPSTF-Ineligible Patients. Cancers (Basel). 2025 Oct 23;17(21):3406. doi: 10.3390/cancers17213406. PMID: 41228201; PMCID: PMC12611041.

Tammemagi CM, Mousavi Janbeh Sarayi SM, Eghbalizarch M, Ishizawa S, Meza R, Toumazis I. P3.01.47 Presentation and Validation of Three Engage Variants of the PLCOm2012 Lung Cancer Risk Prediction Model. J Thorac Oncol. 2025;20(10 Supplement 1): S423.

Eghbalizarch M, Tammemagi CM, Mousavi Janbeh Sarayi SM , Ishizawa S, Meza R, Toumazis I. P1.17.19 Impact of Race and Ethnicity on the ENGAGE-Derived Lung Cancer Screening Recommendations: Implications for Risk Assessment. J Thorac Oncol. 2025;20(10 Supplement 1): S218.

Ishizawa S, Naargund RS, Eghbalizarch M, Tammemagi CM, Meza R, Toumazis I. P1.17.81 Unveiling the Natural History of Lung Cancer by Sex, Histology, and Nodule Type Using Mathematical Modeling. J Thorac Oncol2025;20(10 Supplement 1): S252.

Meyer LA, Ishizawa S, Toumazis I. Use of a natural history model to benchmark progress in managing ovarian cancer. Am J Obstet Gynecol. 2025 Sep 10:S0002-9378(25)00658-1. doi: 10.1016/j.ajog.2025.09.006. Epub ahead of print. PMID: 40939646.

Hemmati M, Mousavi Janbeh Sarayi SM, Toumazis I, Ning MS, Teffera MY, Ausat N, Sareyeldin RM, Hernandez M, Foote R, Busse P, Rosenthal D, Patel SH, Snider JW, Gunn B, Molitaris J, Parvathenini U, Shah SJ, Reddy JP, Lin A, Lee N, Chronowski G, McDonald M, Kalmans N, Katz S, Bajaj GK, Hyde C, Henson CE, Dagan R, Nasiruddin M, Garden AS, Fuller CD, Ma DJ, Frank SJ. EE71 Cost-Effectiveness of Intensity-Modulated Proton Therapy (IMPT) for the Treatment of Head and Neck Oropharyngeal Carcinoma. Value Health. 2025;28(6 Supplement 1): S75.

Yeh PG, Haas A, Sun CC, Lu KH, Meyer LA, Toumazis I. Use Patterns of Levonorgestrel-Releasing Intrauterine System among American Women. Cancer Prev Res (Phila). 2025 May 1;18(5):299-306. doi: 10.1158/1940-6207.CAPR-24-0302. PMID: 39930864.

Myers A, Talwar R, Duan Z, Hensley P, Lotan Y, Williams SB, Luckenbaugh AN, Li R, Kassouf W, Necchi A, Packiam VT, Shore N, Steinberg GD, Witjes F, Schmidt B, Porten S, Hahn N, Bree KK, Toumazis I, Zhao H, Kamat AM. A0796 Cost-effectiveness analysis of treatments for BCG-unresponsive high-risk NMIBC. European Urology. 2025 Mar 1;87:S1636-7.

Fahrmann JF, Irajizad E, Rudsari H, Vykoukal J, Toumazis I, Khorami-Sarvestani S, Ansari S, Yang J, Kettner N, Dennison JB, Ostrin E, Hanash S. Validation of a blood test for multi-cancer risk stratification in a lung cancer screening cohort. medRxiv [Preprint]. 2025 Nov 23:2025.11.20.25340518. doi: 10.1101/2025.11.20.25340518. PMID: 41332848; PMCID: PMC12668053.

Salehjahromi M, Karpinets TV, Sujit SJ, Qayati M, Chen P, Aminu M, Saad MB, Bandyopadhyay R, Hong L, Sheshadri A, Lin J, Antonoff MB, Sepesi B, Ostrin EJ, Toumazis I, Huang P, Cheng C, Cascone T, Vokes NI, Behrens C, Siewerdsen JH, Hazle JD, Chang JY, Zhang J, Lu Y, Godoy MCB, Chung C, Jaffray D, Wistuba I, Lee JJ, Vaporciyan AA, Gibbons DL, Gladish G, Heymach JV, Wu CC, Zhang J, Wu J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer: Proof of concept. Cell Rep Med. 2024 Mar 19;5(3):101463. doi: 10.1016/j.xcrm.2024.101463. Epub 2024 Mar 11. PMID: 38471502; PMCID: PMC10983039.

Ishizawa S, Niu J, Tammemagi MC, Irajizad E, Shen Y, Lu KH, Meyer LA, Toumazis I. Estimating sojourn time and sensitivity of screening for ovarian cancer using a Bayesian framework. J Natl Cancer Inst. 2024 Nov 1;116(11):1798-1806. doi: 10.1093/jnci/djae145. PMID: 39038822.

Nofal S, Niu J, Resong P, Jin J, Merriman KW, Le X, Katki H, Heymach J, Antonoff MB, Ostrin E, Wu J, Zhang J, Toumazis I. Personal history of cancer as a risk factor for second primary lung cancer: Implications for lung cancer screening. Cancer Med. 2024 Mar;13(5):e7069. doi: 10.1002/cam4.7069. PMID: 38466021; PMCID: PMC10926882.

Irajizad E, Fahrmann JF, Toumazis I, Vykoukal J, Dennison JB, Shen Y, Do KA, Ostrin EJ, Feng Z, Hanash S. Biomarker trajectory for earlier detection of lung cancer. EBioMedicine. 2024 Oct;108:105377. doi: 10.1016/j.ebiom.2024.105377. Epub 2024 Sep 30. PMID: 39353277; PMCID: PMC11472629.

Hemmati M, Ishizawa S, Meza R, Ostrin E, Hanash SM, Antonoff M, Schaefer AJ, Tammemägi MC, Toumazis I. Benchmarking lung cancer screening programmes with adaptive screening frequency against the optimal screening schedules derived from the ENGAGE framework: a comparative microsimulation study. EClinicalMedicine. 2024 Jul 28;74:102743. doi: 10.1016/j.eclinm.2024.102743. PMID: 39764179; PMCID: PMC11701438.

Ten Haaf K, de Nijs K, Simoni G, Alban A, Cao P, Sun Z, Yong J, Jeon J, Toumazis I, Han SS, Gazelle GS, Kong CY, Plevritis SK, Meza R, de Koning HJ. The Impact of Model Assumptions on Personalized Lung Cancer Screening Recommendations. Med Decis Making. 2024 Jul;44(5):497-511. doi: 10.1177/0272989X241249182. Epub 2024 May 13. PMID: 38738534; PMCID: PMC11281869.

Hu X, Zhu B, Vokes N, Fujimoto J, Rojas Alvarez FR, Heeke S, Moreira AL, Solis LM, Haymaker C, Velcheti V, Sterman DH, Pass HI, Cheng C, Lee JJ, Zhang J, Wei Z, Wu J, Le X, Ostrin E, Toumazis I, Gibbons D, Su D, Fukuoka J, Antonoff MB, Gerber DE, Li C, Kadara H, Wang L, Davis M, Heymach JV, Hannash S, Wistuba I, Dubinett S, Alexandrov L, Lippman S, Spira A, Futreal AP, Reuben A, Zhang J. The evolution of lung adenocarcinoma precursors is associated with chromosomal instability and transition from innate to adaptive immune response/evasion. Res Sq [Preprint]. 2024 May 15:rs.3.rs-4396272. doi: 10.21203/rs.3.rs-4396272/v1. PMID: 38798564; PMCID: PMC11118701.

Adjei NN, Yeh PG, Haas A, Sun CC, Zhao H, Stone R, Roche KL, Lu KH, Toumazis I, Meyer LA. Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: a cost-effectiveness analysis. Int J Gynecol Cancer. 2025 Dec 19:102884. doi: 10.1016/j.ijgc.2025.102884. Epub ahead of print. PMID: 41605705.

Resong PJ, Niu J, Duhon GF, Foxhall LE, Shete S, Volk RJ, Toumazis I. Acceptability of Personalized Lung Cancer Screening Program Among Primary Care Providers. Cancer Prev Res (Phila). 2024 Feb 2;17(2):51-57. doi: 10.1158/1940-6207.CAPR-23-0359. PMID: 38212272; PMCID: PMC10926168.

Salehjahromi M, Hong L, Li H, Kitsel Y, Godoy M, Wu CC, Antonoff M, Toumazis I, Ostrin E, Heeke S, Vokes NI, Le X, Vaporciyan AA, Lee JJ, Heymach JV, Zhang J, Wu J. 1238 Predicting lung cancer risk with CT radiomics: implications for immunoprevention. J Immunother Cancer. 2024;12(Suppl 2):A1–A1683.

Marqueen K, Garden A, Swanson D, Ning M, Rosenthal D, Gunn G, Fuller C, Phan J, Spiotto M, Lee A, Moreno A, Chronowsk G, Reddy J, Mayo L, Shah S, Gross N, Ferrarotto R, Hutcheson K, Toumazis I, Frank S. Proton therapy reduces gastrostomy-tube dependence in a comparative effectiveness analysis of intensity-modulated proton therapy vs intensity-modulated radiotherapy for oropharyngeal carcinoma. Am J Clin Oncol-Cancer Clinical Trials. 2024 Oct 1; 47(10): S17-S18.

Maki KG, Tan NQP, Volk RJ, Toumazis I. EPH78 Lung Cancer Screening Eligibility and Use in the US: A Cross-Sectional Analysis of 2022 Behavioral Risk Factor Surveillance System Data. Value Health. 2024;27(6 Supplement):S167.

Ostrin E, Fahrmann J, Vykoukal J, Dennison J, Nargund R, Toumazis I, Baron A, Irajizad E, Hanash S. A Four-protein Blood Biomarker Panel Refines a Clinical Risk Score for Indeterminate Pulmonary Nodules. Am J Respir Crit Care Med. 2024;209:A6662.

Neumann AS, Toumazis I, O'Brien JA, Beneventi D, Annam SK, Joy-Thomas A, Volk RJ. Tobacco use and eligibility for lung cancer screening among dental patients at an academic institution in Houston, Texas. Prev Med. 2026 Jan;202:108438. doi: 10.1016/j.ypmed.2025.108438. Epub 2025 Nov 8. PMID: 41213458.

Toumazis I, Cao P, de Nijs K, Bastani M, Munshi V, Hemmati M, Ten Haaf K, Jeon J, Tammemägi M, Gazelle GS, Feuer EJ, Kong CY, Meza R, de Koning HJ, Plevritis SK, Han SS. Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis. Ann Intern Med. 2023 Mar;176(3):320-332. doi: 10.7326/M22-2216. Epub 2023 Feb 7. PMID: 36745885; PMCID: PMC11025620.

Maki KG, Tan NQP, Toumazis I, Volk RJ. Prevalence of Lung Cancer Screening Among Eligible Adults in 4 US States in 2021. JAMA Netw Open. 2023 Jun 1;6(6):e2319172. doi: 10.1001/jamanetworkopen.2023.19172. PMID: 37342043; PMCID: PMC10285576.

Maki KG, Talluri R, Toumazis I, Shete S, Volk RJ. Impact of U.S. Preventive Services Task Force lung cancer screening update on drivers of disparities in screening eligibility. Cancer Med. 2023 Feb;12(4):4647-4654. doi: 10.1002/cam4.5066. Epub 2022 Jul 24. PMID: 35871312; PMCID: PMC9972155.

Li H, Qin K, Zhang Z, Hong L, Wu CC, Godoy MC, Antonoff M, Ostrin EJ, Toumazis I, Gibbons DL, Heymach J, Lee JJ, Wu J, Zhang J. Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival. J Clin Oncol. 2023;41(16 Supplement):8569.

Resong P, Niu J, Duhon G, Foxhall LE, Shete S, Volk RJ, Toumazis I. Lung cancer screening status and acceptability of a personalized approach in Texas. J Clin Oncol. 2023;41(16 Supplement):e22516.

Yeh PG, Toumazis I, Sun C, Lu K, Meyer LA. Abstract 5679: Disparities in uptake of levonorgestrel-releasing intrauterine system (LNG-IUS): implications for uterine cancer primary prevention. Cancer Res. 2023;83(7 Supplement):5769.

Hemmati M, Toumazis I. EP01. 04-002 The Impact of Enforcing a Structure in Lung Cancer Screening Strategy on the Effectiveness and Efficiency of the Screening Program. J Thorac Oncol. 2022;17(9 Supplement):S178-S179.

Meza R, Jeon J, Toumazis I, Ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas DE, Feuer EJ, Plevritis SK, de Koning HJ, Kong CY. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force. JAMA. 2021 Mar 9;325(10):988-997. doi: 10.1001/jama.2021.1077. PMID: 33687469; PMCID: PMC9208912.

Toumazis I, de Nijs K, Cao P, Bastani M, Munshi V, Ten Haaf K, Jeon J, Gazelle GS, Feuer EJ, de Koning HJ, Meza R, Kong CY, Han SS, Plevritis SK. Cost-effectiveness Evaluation of the 2021 US Preventive Services Task Force Recommendation for Lung Cancer Screening. JAMA Oncol. 2021 Dec 1;7(12):1833-1842. doi: 10.1001/jamaoncol.2021.4942. PMID: 34673885; PMCID: PMC8532037.

Toumazis I, Alagoz O, Leung A, Plevritis SK. A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings. Cancer. 2021 Dec 1;127(23):4432-4446. doi: 10.1002/cncr.33835. Epub 2021 Aug 12. PMID: 34383299; PMCID: PMC8578300.

Toumazis I, Erdogan SA, Bastani M, Leung A, Plevritis SK. A Cost-Effectiveness Analysis of Lung Cancer Screening With Low-Dose Computed Tomography and a Diagnostic Biomarker. JNCI Cancer Spectr. 2021 Oct 6;5(6):pkab081. doi: 10.1093/jncics/pkab081. PMID: 34738073; PMCID: PMC8564700.

Harrison RF, Cantor SB, Sun CC, Villanueva M, Westin SN, Fleming ND, Toumazis I, Sood AK, Lu KH, Meyer LA. Cost-effectiveness of laparoscopic disease assessment in patients with newly diagnosed advanced ovarian cancer. Gynecol Oncol. 2021 Apr;161(1):56-62. doi: 10.1016/j.ygyno.2021.01.024. Epub 2021 Jan 31. PMID: 33536126; PMCID: PMC8247119.

Bastani M, Toumazis I, Hedou' J, Leung A, Plevritis SK. Evaluation of Alternative Diagnostic Follow-up Intervals for Lung Reporting and Data System Criteria on the Effectiveness of Lung Cancer Screening. J Am Coll Radiol. 2021 Dec;18(12):1614-1623. doi: 10.1016/j.jacr.2021.08.001. Epub 2021 Aug 19. PMID: 34419477.

Meza R, Jeon J, Toumazis I, ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas D, Feuer EJ, Plevritis SK, de Koning HJ Kong CY. Appendix A: CISNET Lung Model Descriptions. In: Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: A Collaborative Modeling Study for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Mar. (Evidence Syntheses, No. 198tr.) 

Bastani M, Toumazis I, Plevritis SK, Hedou' J, Leung A. MA05.09 Evaluation of Alternative Diagnostic Follow-Up Intervals for Lung-RADs Criteria on the Effectiveness of Lung Cancer Screening. J Thorac Oncol. 2021;16(3 Supplement):S150-S151.

Toumazis I, Bastani M, Han SS, Plevritis SK. Risk-Based lung cancer screening: A systematic review. Lung Cancer. 2020 Sep;147:154-186. doi: 10.1016/j.lungcan.2020.07.007. Epub 2020 Jul 12. PMID: 32721652.

Ten Haaf K, Bastani M, Cao P, Jeon J, Toumazis I, Han SS, Plevritis SK, Blom EF, Kong CY, Tammemägi MC, Feuer EJ, Meza R, de Koning HJ. A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies. J Natl Cancer Inst. 2020 May 1;112(5):466-479. doi: 10.1093/jnci/djz164. PMID: 31566216; PMCID: PMC7225672.

Han SS, Chow E, Ten Haaf K, Toumazis I, Cao P, Bastani M, Tammemagi M, Jeon J, Feuer EJ, Meza R, Plevritis SK. Disparities of National Lung Cancer Screening Guidelines in the US Population. J Natl Cancer Inst. 2020 Nov 1;112(11):1136-1142. doi: 10.1093/jnci/djaa013. PMID: 32040195; PMCID: PMC7669226.

Meza R, Jeon J, Toumazis I, ten Haaf K, Cao P, Bastani M, Han SS, Blom EF, Jonas D, Feuer EJ, Plevritis SK, de Koning HJ, Kong CY. Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: A Collaborative Modeling Study for the U.S. Preventive Services Task Force [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2021 Mar. Report No.: 20-05266-EF-2. PMID: 33750088.

Criss SD, Cao P, Bastani M, Ten Haaf K, Chen Y, Sheehan DF, Blom EF, Toumazis I, Jeon J, de Koning HJ, Plevritis SK, Meza R, Kong CY. Cost-Effectiveness Analysis of Lung Cancer Screening in the United States: A Comparative Modeling Study. Ann Intern Med. 2019 Dec 3;171(11):796-804. doi: 10.7326/M19-0322. Epub 2019 Nov 5. PMID: 31683314.

Tammemägi MC, Ten Haaf K, Toumazis I, Kong CY, Han SS, Jeon J, Commins J, Riley T, Meza R. Development and Validation of a Multivariable Lung Cancer Risk Prediction Model That Includes Low-Dose Computed Tomography Screening Results: A Secondary Analysis of Data From the National Lung Screening Trial. JAMA Netw Open. 2019 Mar 1;2(3):e190204. doi: 10.1001/jamanetworkopen.2019.0204. PMID: 30821827; PMCID: PMC6484623.

Toumazis I, Tsai EB, Erdogan SA, Han SS, Wan W, Leung A, Plevritis SK. Cost-Effectiveness Analysis of Lung Cancer Screening Accounting for the Effect of Indeterminate Findings. JNCI Cancer Spectr. 2019 May 23;3(3):pkz035. doi: 10.1093/jncics/pkz035. PMID: 31942534; PMCID: PMC6947892.

Toumazis I, Alagoz O, Leung A, Plevritis S. P2. 11-02 individualized risk-based lung cancer screening incorporating past screening findings and changes in smoking behaviors. J Thorac Oncol. 2019;14(10 Supplement):S792.

Han S, Chow E, ten Haaf K, Toumazis I, Bastani M, Tammemagi M, Jeon J, Feuer E, Meza R, Plevritis S. P1. 11-03 Disparities and National Lung Cancer Screening Guidelines in the US Population. J Thorac Oncol. 2019;14(10 Supplement):S515-S516.

Han SS, Erdogan SA, Toumazis I, Leung A, Plevritis SK. Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model. Cancer Causes Control. 2017 Sep;28(9):947-958. doi: 10.1007/s10552-017-0907-x. Epub 2017 Jul 12. PMID: 28702814; PMCID: PMC5880208.

Toumazis I, Kurt M, Toumazi A, Karacosta LG, Kwon C. Comparative Effectiveness of Up To Three Lines of Chemotherapy Treatment Plans for Metastatic Colorectal Cancer. MDM Policy Pract. 2017 Aug 30;2(2):2381468317729650. doi: 10.1177/2381468317729650. PMID: 30288431; PMCID: PMC6124942.

Toumazis I, Kwon C. Worst-case conditional value-at-risk minimization for hazardous materials transportation. Transportation Science. 2016.

Toumazis I. Dynamic Chemotherapy Scheduling for Metastatic Colorectal Cancer Patients: Assessments and Improvements. Dissertation. 2015.

Toumazis I, Kwon C. Routing hazardous materials on time-dependent networks using conditional value-at-risk. Transportation Research Part C: Emerging Technologies. 2013.

Toumazis I, Kwon C, Batta R. Value-at-risk and conditional value-at-risk minimization for hazardous materials routing. Handbook of OR/MS Models in Hazardous Materials Transportation. 2013.

Toumazis I, Kwon C. Robust Routing for Hazardous Materials Transportation with Conditional Value-at-Risk on Time-Dependent Networks. 2012.